Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedJun 05, 2025
DataAggregated Company Financials
Companies297
  • 7D3.4%
  • 3M-11.9%
  • 1Y-9.6%
  • YTD-4.1%

The Pharma industry is up 3.4% in the last week, with Eli Lilly up 6.5%. Meanwhile, Corcept Therapeutics actually underperformed within the industry, shrinking 9.9% in the last week. However, the industry is down 9.6% over the past year. Looking forward, earnings are forecast to grow by 14% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 05 Jun 2025US$1.7tUS$382.7bUS$61.2b17.9x27.7x4.4x
Sat, 03 May 2025US$1.7tUS$382.7bUS$63.7b17.2x27.3x4.5x
Mon, 31 Mar 2025US$1.8tUS$380.6bUS$41.3b15.8x44.8x4.9x
Wed, 26 Feb 2025US$1.9tUS$381.1bUS$39.2b18.2x48.9x5x
Fri, 24 Jan 2025US$1.8tUS$370.4bUS$30.5b18.4x57.9x4.8x
Sun, 22 Dec 2024US$1.8tUS$369.4bUS$31.1b16.7x57.2x4.8x
Tue, 19 Nov 2024US$1.8tUS$373.9bUS$30.5b19x58.5x4.8x
Thu, 17 Oct 2024US$2.0tUS$365.3bUS$23.7b18.8x85.8x5.6x
Sat, 14 Sep 2024US$2.0tUS$364.2bUS$25.5b18.8x80.1x5.6x
Mon, 12 Aug 2024US$2.0tUS$362.1bUS$22.0b16.7x89.6x5.4x
Wed, 10 Jul 2024US$2.0tUS$357.6bUS$13.8b15.4x141.9x5.5x
Fri, 07 Jun 2024US$1.9tUS$358.3bUS$14.1b15.5x135.6x5.3x
Sun, 05 May 2024US$1.8tUS$358.0bUS$13.8b21.4x131.1x5.1x
Tue, 02 Apr 2024US$1.9tUS$355.2bUS$22.7b22.5x84.2x5.4x
Thu, 29 Feb 2024US$1.9tUS$355.1bUS$23.8b24.3x80x5.4x
Sat, 27 Jan 2024US$1.8tUS$375.2bUS$33.9b24.6x51.6x4.7x
Mon, 25 Dec 2023US$1.7tUS$375.1bUS$33.9b32x49.3x4.4x
Wed, 22 Nov 2023US$1.6tUS$375.1bUS$33.9b25.8x48.1x4.4x
Fri, 20 Oct 2023US$1.7tUS$382.7bUS$44.7b17.6x37x4.3x
Sun, 17 Sep 2023US$1.7tUS$381.8bUS$43.9b18x39.2x4.5x
Tue, 15 Aug 2023US$1.8tUS$381.5bUS$43.8b19x40.5x4.7x
Thu, 13 Jul 2023US$1.7tUS$392.8bUS$60.2b18.2x27.5x4.2x
Sat, 10 Jun 2023US$1.7tUS$393.0bUS$60.5b18.6x28.4x4.4x
Mon, 08 May 2023US$1.7tUS$393.0bUS$59.5b19.4x28.9x4.4x
Wed, 05 Apr 2023US$1.6tUS$401.2bUS$69.4b15.6x23.1x4x
Fri, 03 Mar 2023US$1.6tUS$401.3bUS$69.6b18.3x22.3x3.9x
Sun, 29 Jan 2023US$1.7tUS$402.6bUS$69.4b17.7x24x4.1x
Tue, 27 Dec 2022US$1.8tUS$403.7bUS$70.7b16.8x24.8x4.4x
Thu, 24 Nov 2022US$1.7tUS$403.7bUS$70.7b15.4x24.6x4.3x
Sat, 22 Oct 2022US$1.6tUS$403.4bUS$72.1b13.2x22.5x4x
Mon, 19 Sep 2022US$1.6tUS$403.0bUS$71.3b13.8x22.3x3.9x
Wed, 17 Aug 2022US$1.7tUS$403.0bUS$70.0b15.1x23.6x4.1x
Fri, 15 Jul 2022US$1.7tUS$392.4bUS$65.1b21.7x25.7x4.3x
Sun, 12 Jun 2022US$1.6tUS$392.5bUS$64.7b20.7x24.9x4.1x
Price to Earnings Ratio

24.9x


Total Market Cap: US$1.6tTotal Earnings: US$64.7bTotal Revenue: US$392.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 51.9x202320242025
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 27.7x which is lower than its 3-year average PE of 51.9x.
  • The industry is trading close to its 3-year average PS ratio of 4.6x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.40%
Healthcare1.93%
Pharma3.44%
Pharma3.44%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$765.846.5%
+US$41.7b		-7.9%PE61.9x
MRK MerckUS$78.272.8%
+US$5.3b		-39.5%PE11.3x
BMY Bristol-Myers SquibbUS$47.952.1%
+US$2.0b		16.3%PE18x
JNJ Johnson & JohnsonUS$153.220.5%
+US$1.9b		5.0%PE16.9x
RGC Regencell Bioscience HoldingsUS$630.1021.2%
+US$1.4b		13,392.5%PB997.7x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlans & PricingLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & EnterpriseWhat's New
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

XERS

US$4.43

Xeris Biopharma Holdings

7D

-7.3%

1Y

82.3%

TLRY

US$0.41

Tilray Brands

7D

-9.0%

1Y

-77.1%

ZTS

US$168.59

Zoetis

7D

1.9%

1Y

-4.1%

CORT

US$69.98

Corcept Therapeutics

7D

-9.9%

1Y

103.2%

JNJ

US$153.22

Johnson & Johnson

7D

0.5%

1Y

5.0%

LLY

US$765.84

Eli Lilly

7D

6.5%

1Y

-7.9%

MRK

US$78.27

Merck

7D

2.8%

1Y

-39.5%

PRGO

US$26.26

Perrigo

7D

-3.1%

1Y

-0.5%

PFE

US$23.39

Pfizer

7D

0.9%

1Y

-20.8%

ETON

US$16.95

Eton Pharmaceuticals

7D

-15.6%

1Y

365.7%

BMY

US$47.95

Bristol-Myers Squibb

7D

2.1%

1Y

16.3%

TEVA

US$17.52

Teva Pharmaceutical Industries

7D

-3.5%

1Y

3.8%

TVRD

US$24.34

Tvardi Therapeutics

7D

-21.1%

1Y

n/a

RGC

US$630.10

Regencell Bioscience Holdings

7D

21.2%

1Y

13,392.5%

VRNA

US$83.98

Verona Pharma

7D

13.6%

1Y

591.8%

author-image

Ohtuvayre Launch And EU Approval Will Unlock Future Markets

Rapid adoption of Ohtuvayre for COPD and strong prescription growth suggest significant future revenue potential.

ZYBT

US$6.43

Zhengye Biotechnology Holding

7D

-26.9%

1Y

n/a